88 related articles for article (PubMed ID: 29489023)
1. KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma.
Mehrad M; Roy S; LaFramboise WA; Petrosko P; Miller C; Incharoen P; Dacic S
Histopathology; 2018 Aug; 73(2):207-214. PubMed ID: 29489023
[TBL] [Abstract][Full Text] [Related]
2. [Clinical characteristics and prognosis analysis of pulmonary sarcomatoid carcinoma].
Feng XY; Chen MJ; Xu Y; Zhong W; Liu XY; Gao XX; Zhao J; Wang MZ
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):319-324. PubMed ID: 38599806
[No Abstract] [Full Text] [Related]
3. Next-Generation DNA Sequencing of Grade 1 Meningioma Tumours: A Case Report of Angiomatous and Psammomatous Meningiomas.
Taher MM; Ashour KM; Althaqafi BA; Mansouri A; Al-Harbi AA; Filfilan W; Bakhsh GY; Bantan NA; Saeed M; AlQuthami K
Cureus; 2024 Feb; 16(2):e54009. PubMed ID: 38476782
[TBL] [Abstract][Full Text] [Related]
4. Savolitinib as a novel treatment regimen for pulmonary sarcomatoid carcinoma with MET exon 14 skipping mutation.
Wang Y; Bu Y; Che G
Asian J Surg; 2024 Apr; ():. PubMed ID: 38599970
[No Abstract] [Full Text] [Related]
5. Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
Domblides C; Leroy K; Monnet I; Mazières J; Barlesi F; Gounant V; Baldacci S; Mennecier B; Toffart AC; Audigier-Valette C; Doucet L; Giroux-Leprieur E; Guisier F; Ricordel C; Molinier O; Perol M; Pichon E; Robinet G; Templement-Grangerat D; Ruppert AM; Rabbe N; Antoine M; Wislez M
J Thorac Oncol; 2020 May; 15(5):860-866. PubMed ID: 31991225
[TBL] [Abstract][Full Text] [Related]
6. Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.
Liu X; Wang F; Xu C; Chen X; Hou X; Li Q; Li P; Xie Z; Liu Y; Chang L; Guan Y; Zhang X; Yang L; Wang H; Yi X; Zhang J; Xia X; Moran C; Chen L
Oncogene; 2021 Jan; 40(4):821-832. PubMed ID: 33273725
[TBL] [Abstract][Full Text] [Related]
7. Poor prognosis of pulmonary sarcomatoid carcinoma with
Chen F; Gu Q; Hu C; Cai X; Lei S
Onco Targets Ther; 2019; 12():3321-3325. PubMed ID: 31118683
[TBL] [Abstract][Full Text] [Related]
8. MET alterations in advanced pulmonary sarcomatoid carcinoma.
Gong C; Xiong H; Qin K; Wang J; Cheng Y; Zhao J; Zhang J
Front Oncol; 2022; 12():1017026. PubMed ID: 36212500
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of advanced pulmonary sarcomatoid carcinoma with the PD-1 inhibitor toripalimab: A case report.
Jiao Y; Liu M; Luo N; Guo H; Li J
Oral Oncol; 2021 Jan; 112():104992. PubMed ID: 32943323
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of
Yu Y; Zhang Q; Zhang J; Lu S
J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
[TBL] [Abstract][Full Text] [Related]
11. Genomic Landscape of Pulmonary Sarcomatoid Carcinoma.
Kwon HJ; Lee S; Han YB; Lee J; Kwon S; Kim H; Chung JH
Cancer Res Treat; 2024 Apr; 56(2):442-454. PubMed ID: 37973906
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for rare lung cancers: Status, challenges, and prospects.
Wang C; Yuan X; Xue J
Mol Ther; 2023 Jul; 31(7):1960-1978. PubMed ID: 37179456
[TBL] [Abstract][Full Text] [Related]
13. Demographics and Clinicopathologic Profile of Pulmonary Sarcomatoid Carcinoma with Survival Analysis and Genomic Landscape.
Ullah A; Ahmed A; Yasinzai AQK; Lee KT; Khan I; Asif B; Khan I; Tareen B; Kakar K; Andam G; Heneidi S; Khan J; Khan H; Karki NR; Del Rivero J; Karim NA
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173936
[No Abstract] [Full Text] [Related]
14. Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma.
Garcia D; Mambetsariev I; Fricke J; Schmolze D; Afkhami M; Mannan R; Kim P; Therese Dingal S; Nguyen B; Babikian R; Fong Y; Salgia R
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37160318
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and prognostic factors of pulmonary sarcomatoid carcinoma.
Zhao C; Gao S; Xue Q; Tan F; Gao Y; Mao Y; Wang D; Zhao J; Yang D; Hong Q; Mu J
J Thorac Dis; 2022 Oct; 14(10):3773-3781. PubMed ID: 36389311
[TBL] [Abstract][Full Text] [Related]
16. Significant response of pulmonary sarcomatoid carcinoma with obstructive atelectasis to treatment with the PD-1 inhibitor camrelizumab combined with transbronchial cryoablation: A case report and literature review.
Nian J; Zhu Y; Fu Q; Yang G; Wang X
Front Oncol; 2022; 12():1013047. PubMed ID: 36387200
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotyping of pulmonary sarcomatoid carcinoma.
Ma Y; Li W; Li Z; Chen J; Wang H; Jiang T; Zhu J
Front Immunol; 2022; 13():976739. PubMed ID: 36341325
[TBL] [Abstract][Full Text] [Related]
18. The Impact of
Ardito F; Razionale F; Campisi A; Carlino A; Vellone M; Vani S; Larocca LM; Giuliante F
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139531
[No Abstract] [Full Text] [Related]
19. Pten and p53 Loss in the Mouse Lung Causes Adenocarcinoma and Sarcomatoid Carcinoma.
Lázaro S; Lorz C; Enguita AB; Seller I; Paramio JM; Santos M
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954335
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Pulmonary sarcomatoid carcinoma complicating TP53 mutation treated successfully with Tislelizumab combined with Anlotinib-a case report.
Li YF; Zhao XF; Tian Y; Xiao XY; Yan CY; Shen H
Front Genet; 2022; 13():949989. PubMed ID: 35938033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
